Servier's sevasemten missed its pivotal Becker muscular dystrophy trial, while Karyopharm filed Chapter 11 and proposed an Ayrmid deal around XPOVIO. This delayed November 3, 2026 edition reports dated developments: 'today' means November 3 and 'Monday' November 2. Also covered: uniQure's AMT-130 application, Teva's TOPAS-MSA stop, FDA potency guidance, InventisBio's psoriasis results, Recursion's REC-4881 data, Dr. Reddy's tentative lenacapavir approval reported by CHAI, Rhythm's LG Chem amendment and Pfizer's forecast.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →